I131

DRUG2 trials

Sponsors

Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Center, Korea

Conditions

Low Risk Differentiated Thyroid CancerThyroid Neoplasms

Phase 2

Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer

National Cancer Center, KoreaThyroid Neoplasms

Start: 2013-05-31End: 2020-12-31Target: 556Updated: 2017-01-20

Phase 3

Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?

Active, not recruitingNCT01837745

Gustave Roussy, Cancer Campus, Grand ParisLow Risk Differentiated Thyroid Cancer

Start: 2013-05-13End: 2030-01-01Updated: 2023-05-17

Related Papers

Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.

2024-11-2215 citations

Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer

New England Journal of Medicine2022-03-09210 citations

Estimabl2: Is There a Need for Radioiodine Ablation in Low Risk Differentiated Thyroid Cancer (DTC) Patients?: Results From the French Randomized Phase III Prospective Trial on 776 Patients (NCT 01837745)

Journal of the Endocrine Society2021-05-0117 citations

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.

2018-11-2777 citations